A detailed history of American Century Companies Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 39,115 shares of DSGN stock, worth $181,884. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,115
Previous 32,634 19.86%
Holding current value
$181,884
Previous $175,000 37.71%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$4.56 - $7.5 $29,553 - $48,607
6,481 Added 19.86%
39,115 $241,000
Q3 2024

Nov 12, 2024

BUY
$3.19 - $5.88 $36,050 - $66,449
11,301 Added 52.97%
32,634 $175,000
Q2 2024

Aug 07, 2024

BUY
$3.23 - $4.77 $68,905 - $101,758
21,333 New
21,333 $71,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $260M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.